Effects of evolocumab on immune cells activation in human atherosclerotic plaques

Background and Aims: Evolocumab, an anti-PCSK9 antibody, is used to reduce LDL-cholesterol level in patients with cardiovascular diseases. At the same time, it was found, that PCSK9 itself is involved not only in lipids metabolism but also in inflammatory process. The aim of our study was to investigate the effects of the evolocumab treatment on T-cell activation in human atherosclerotic plaques.